Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BNT3211 · 1 trial · 1 indication
DLT period defined as the first 21 days. Per dose level.
Per dose level (Part A) and per arm (Part B).
Per dose level (Part A) and per arm (Part B).
Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response. Per arm.
| Arm | Type | Description |
|---|---|---|
| Part A (dose escalation) - BNT3211 monotherapy | EXPERIMENTAL | Escalating dose levels of BNT3211. |
| Part B (dose optimization) - BNT3211 monotherapy | EXPERIMENTAL | Indications as in Part A. Doses will be selected from Part A. |
| Name | Type | Description |
|---|---|---|
| BNT3211 | BIOLOGICAL | Intravenous infusion |
Key Inclusion Criteria: * Are ≥18 years of age (local laws will be followed if the age of consent is older). * Have an Eastern Cooperative Oncology Group performance status of 0 to 1. * Have a life expectancy of ≥3 months in the opinion of the investigator. * Have at least one measurable lesion as ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BNT3211 is an investigational biologic being studied for the treatment of advanced solid tumors. It is in Phase 1/2 clinical development and is not yet available as a marketed therapy. The study enrolls adults 18 years and older with advanced solid tumors.
BNT3211 is being developed by BioNTech SE, which trades on Nasdaq under the ticker BNTX. BioNTech is the sponsor of the first-in-human study evaluating the agent in advanced solid tumors.
BNT3211 is in Phase 1/2 development. It is investigational and is being evaluated in a first-in-human dose escalation and expansion study. No Phase 3 trial of BNT3211 has been registered.
BNT3211 is being studied in NCT07951359, a first-in-human, dose escalation, and expansion study for participants with advanced solid tumors. The trial is Phase 1/Phase 2, is not yet recruiting, and plans to enroll 345 participants aged 18 years and older.
No. The BNT3211 study enrolls participants with advanced solid tumors without a biomarker-selection requirement, and it accepts all sexes among adults 18 years and older. The trial is controlled but is not randomized and is not double-blind.